Oyster_Point_Social.jpg
Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
June 21, 2021 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
June 21, 2021 07:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
June 10, 2021 07:00 ET | Oyster Point Pharma, Inc.
Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technologyOyster Point Pharma plans to discuss the potential for...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
June 03, 2021 08:00 ET | Oyster Point Pharma, Inc.
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK)Preclinical study results from a 42-day...
Oyster_Point_Social.jpg
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 06, 2021 16:01 ET | Oyster Point Pharma, Inc.
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDAOLYMPIA Phase 2 Study on Track,...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
May 01, 2021 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
April 30, 2021 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces New Appointment to Board of Directors
April 05, 2021 06:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
March 02, 2021 06:00 ET | Oyster Point Pharma, Inc.
Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss...
Oyster_Point_Social.jpg
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
February 25, 2021 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...